Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

Technology Stocks News 17

In June, Esperion Therapeutics Inc. (NASDAQ:ESPR), an Ann Arbor-based early-stage pharmaceutical company, raised $73 million in its IPO. It plans a secondary offering this year, based on trial results of its cholesterol-lowering drug. Esperion Therapeutics Inc (NASDAQ:ESPR) stock performance was -5.04% in last session and finished the day at $14.69. Traded volume was 31,400 shares in the last session and the average volume of the stock remained 44.46K shares.

The 2014 Annual Meeting of Stockholders (the “Annual Meeting”) of Egalet Corporation (NASDAQ:EGLT) was held on June 9, 2014. Matters submitted to the stockholders and voted upon at the meeting, which are more fully described in the Company’s Proxy Statement, which was originally filed with the Securities and Exchange Commission on April 30, 2014 and revised pursuant to a filing with the Securities and Exchange Commission on May 6, 2014, were (1) the election of Mr. Robert Radie as a Class A director to the Company’s board of directors. Egalet Corp (NASDAQ:EGLT) dropped -5.10 percent to $12.65 Thursday on volume of 50,740 shares. The intra-day range of the stock was $12.54 to $14.70. Egalet Corp (NASDAQ:EGLT) has a market capitalization of $215.06million.

Ocera Therapeutics Inc (NASDAQ:OCRX) is developing OCR-002 for reducing ammonia toxicity in patients with liver damage. Analysts estimated the market for the drug could exceed $500 million. Ocera Therapeutics Inc (NASDAQ:OCRX)’s stock on June 12, 2014 reported a decrease of -6.12% to the closing price of $7.36. Its fifty two weeks range is $2.00 -$19.94. The total market capitalization recorded $114.39million. The overall volume in the last trading session was 62,840.00million shares. In its share capital, OCRX has 15.55million outstanding shares.

Yesterday, small cap La Jolla Pharmaceutical Company (NASDAQ:LJPC) was attracting some extra attention when it announced the completion of enrollment in a Phase 2 extension study of GCS-100 in chronic kidney disease, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks or peers like Galectin Therapeutics Inc (NASDAQ: GALT) and BG Medicine, Inc (NASDAQ: BGMD) in the galectin space and Intercept Pharmaceuticals Inc (NASDAQ: ICPT) – a stock that surged earlier this year when it was granted fast track study for a liver treatment. On Thursday, shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) dropped -6.97% to close the day at $8.48. Company monthly performance is recorded as -3.25%. La Jolla Pharmaceutical Company (NASDAQ:LJPC) quarterly revenue growth is -42.93%.

Omeros Corporation (NASDAQ:OMER) had a breakout on Tuesday. This junior biotech has been playing catch-up and has turned around to reach this year’s high. It pulled back and consolidated, and resistance was taken out with a thrust. It could move into the channel line at about 21. Omeros Corporation (NASDAQ:OMER) stock performance was -10.14% in last session and finished the day at $14.26. Traded volume was 818,108.00million shares in the last session and the average volume of the stock remained 494.55K shares. The beta of the stock remained 0.95. Omeros Corporation (NASDAQ:OMER) insider ownership is 5.10%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone